Lifeboat Foundation

Life Biosciences is a company co-founded by the celebrity geroscientist David Sinclair and is based on his Harvard team’s research into partial cellular reprogramming. In the heated race to translate this promising technology to the clinic, Life has emerged as one of the favorites, inching closer towards clinical trials in humans. Life is counting on its proprietary reprogramming technology that uses only three out of four classic reprogramming factors and on its strong team of scientists and managers. We talked to Dr. Sharon Rosenzweig-Lipson, Life’s Chief Scientific Officer, about the company’s journey, delving deep into the technology and its future.

I’ll start by saying that Life Biosciences is one of the most exciting companies in the longevity field. You might actually become the first company to have a partial reprogramming-based therapy approved.

At Life Biosciences, we’re focused on something that matters to everyone: helping people stay healthier as they age. We’re working on what we call cellular rejuvenation technologies, basically finding ways to turn back the clock in cells and make them more youthful. I came on board as Chief Scientific Officer about a year and a half ago, but I actually got to know the company pretty well before that. I consulted for them for a year, which gave me a chance to look under the hood, see the science they were doing, and I got really excited about what I saw.

Donate to Closer To Truth and help us keep our content free and without paywalls: https://shorturl.at/OnyRq.

What is information in biology? information is essential for analyzing data and testing hypotheses. But what is information in evolution, population genetics, levels of selection, and molecular genetics? Is computational biology transformational?

Continue reading “Terrence Deacon — Philosophy of Biological Information” »

In this episode of Cosmology 101, we learn how the detection of the Cosmic Microwave Background (CMB) validated the Big Bang Theory and led to the development of the concept of cosmic inflation.

Explore the challenges and ongoing debates in cosmology as scientists seek to uncover the true nature of the early universe and the origins of cosmic structure.

Continue reading “Cosmic Inflation Explained | Cosmology 101 Episode 6” »

Physicists in Germany have used visible light to measure intramolecular distances smaller than 10 nm thanks to an advanced version of an optical fluorescence microscopy technique called MINFLUX. The technique, which has a precision of just 1 angstrom (0.1 nm), could be used to study biological processes such as interactions between proteins and other biomolecules inside cells.

In conventional microscopy, when two features of an object are separated by less than half the wavelength of the light used to image them, they will appear blurry and indistinguishable due to diffraction. Super-resolution microscopy techniques can, however, overcome this so-called Rayleigh limit by exciting individual fluorescent groups (fluorophores) on molecules while leaving neighbouring fluorophores alone, meaning they remain dark.

One such technique, known as nanoscopy with minimal photon fluxes, or MINFLUX, was invented by the physicist Stefan Hell. First reported in 2016 by Hell’s team at the Max Planck Institute (MPI) for Multidisciplinary Sciences in Göttingen, MINFLUX first “switches on” individual molecules, then determines their position by scanning a beam of light with a doughnut-shaped intensity profile across them.

Is AI going to take your job? Here’s what Nvidia CEO Jensen Huang told Bollywood star Akshay Kumar.

Read more on the chip giant’s partnerships with the biggest Indian corporates, including Ambani’s Reliance, announced at Nvidia’s AI summit in Mumbai.

Nvidia Corp.’s Jensen Huang struck a partnership with Asia’s richest man, Mukesh Ambani, to build out artificial intelligence infrastructure and spur the technology’s adoption in the world’s most populous country.

China has just launched the world’s first autonomous flying taxis, cutting a 1-hour drive down to just 7 minutes!

These eVTOL (electric Vertical Take-Off and Landing) aircraft feature 16 propellers and carry two passengers up to 30–40 km. They offer a thrilling glimpse into the future of urban transport. Each pilot-free flight is safely monitored from a high-tech command center.

What do you think about this? ☝️

Accumulation of senescent cells drives aging and age-related diseases. Senolytics, which selectively kill senescent cells, offer a promising approach for treating many age-related diseases. Using a senescent cell-based phenotypic drug discovery approach that combines drug screening and drug design, we developed two novel flavonoid senolytics, SR29384 and SR31133, derived from the senolytic fisetin. These compounds demonstrated enhanced senolytic activities, effectively eliminating multiple senescent cell types, reducing tissue senescence in vivo, and extending healthspan in a mouse model of accelerated aging. Mechanistic studies utilizing RNA-Seq, machine learning, network pharmacology, and computational simulation suggest that these novel flavonoid senolytics target PARP1, BCL-xL, and CDK2 to induce selective senescent cell death. This phenotype-based discovery of novel flavonoid senolytics, coupled with mechanistic insights, represents a key advancement in developing next-generation senolyticss with potential clinical applications in treating aging and age-related diseases.

LJN and PDR are cofounders of Itasca Therapeutics, developing senotherapeutics for aging and age-related diseases. LJZ, LJN, PDR and the University of Minnesota have filed a provisional patent on the application of flavonoid analogs, including SR29384 and SR31133, as a strategy to treat age-related diseases.

Joscha Bach, a prominent cognitive scientist and AI researcher, explores the essence of artificial intelligence and consciousness. Bach elaborates on the history and philosophical underpinnings of AI, tracing its roots from Aristotle to contemporary deep learning. He discusses the current challenges and limitations in machine learning, particularly in achieving human-like understanding and consciousness.

Bach raises critical questions about the alignment of AI with human values and the feasibility of building systems smarter and more ethical than humans. He delves into the nature of consciousness, proposing that it is not merely a computational process but a fundamental aspect of how minds perceive and interact with the world. Bach also addresses the potential and risks of advanced AI, emphasizing the need for ethical considerations and a deeper understanding of consciousness to guide future developments.

Continue reading “Machine Consciousness | Joscha Bach” »

The 3 Body Problem Explored: Cosmic Sociology, Longtermism & Existential Risk — round table discussion with three great minds: Robin Hanson, Anders Sandberg and Joscha Bach — moderated by Adam Ford (SciFuture) and James Hughes (IEET).

Some of the items discussed:
- How can narratives that keep people engaged avoid falling short of being realistic?
- In what ways is AI superintelligence kept of stage to allow a narrative that is familiar and easier to make sense of?
- Differences in moral perspectives — moral realism, existentialism and anti-realism.
- Will values of advanced civilisations converge to a small number of possibilities, or will they vary greatly?
- How much will competition be the dominant dynamic in the future, compared to co-ordination?
- In a competitive dynamic, will defense or offense be the most dominant strategy?

Continue reading “The 3 Body Problem Explored — Robin Hanson, Anders Sandberg & Joscha Bach” »